Cellectar Biosciences Business Summary

Cellectar Biosciences, Inc. (CLRB) is a late-stage clinical biopharmaceutical company that generates revenue through the development and future commercialization of its proprietary Phospholipid Drug Conjugate (PDC) delivery platform. The company operates as a single business segment focused on targeted radiotherapeutics for cancer, utilizing its PLE (phospholipid ether) technology to deliver cytotoxic payloads directly to malignant cells while minimizing off-target toxicity. Its lead therapeutic candidate, iopofosine I 131, is currently advancing toward a Conditional Marketing Authorization (CMA) filing with the EMA in Q3 2026 for Waldenstrom’s macroglobulinemia, alongside an accelerated approval pathway with the FDA. Cellectar competes directly with radiopharmaceutical and oncology-focused firms such as Fusion Pharmaceuticals, RayzeBio, Clarity Pharmaceuticals, and Agenus, positioning itself as a specialized player in the high-precision radiotherapeutic market with a focus on rare and orphan cancer indications. The company’s foundational PDC technology was developed by Jamey Weichert, Ph.D., who serves as the Technology Founder and Chief Scientific Officer. The executive leadership is headed by President and CEO James V. Caruso, who joined in 2015 with over 35 years of experience at multinational firms including Novartis, Bristol-Myers Squibb, and BASF Pharmaceuticals-Knoll. The management team includes Chief Operating Officer Jarrod Longcor, formerly of Avillion LLP and Rib-X Pharmaceuticals, and CFO Chad Kolean, who previously held financial leadership roles at Vivex Biologics and Titan Spine. The board is chaired by Douglas J. Swirsky and includes notable members such as Dr. Asher Chanan-Khan, a professor at the Mayo Clinic. Cellectar is supported by a mix of institutional and mutual fund investors, including Raymond James Financial Services and Dimensional Fund Advisors.